Cryo-Cell (CCEL) stock price, revenue, and financials

Cryo-Cell market cap is $63.4 m, and annual revenue was $31.82 m in FY 2019

$63.4 M

CCEL Mkt cap, 25-Jan-2021

$8.1 M

Cryo-Cell Revenue Q3, 2020
Cryo-Cell Gross profit (Q3, 2020)5.8 M
Cryo-Cell Gross profit margin (Q3, 2020), %70.9%
Cryo-Cell Net income (Q3, 2020)784.5 K
Cryo-Cell EBIT (Q3, 2020)2.5 M
Cryo-Cell Cash, 31-Aug-20208.1 M
Cryo-Cell EV63.2 M

Cryo-Cell Revenue

Cryo-Cell revenue was $31.82 m in FY, 2019 which is a 8.9% year over year increase from the previous period.

Embed Graph

Cryo-Cell Revenue Breakdown

Embed Graph

Cryo-Cell revenue breakdown by business segment: 97.4% from Umbilical Cord Blood and Cord Tissue Stem Cell Service and 2.6% from Other

Cryo-Cell Income Statement

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Revenue

23.1m25.4m29.2m31.8m

Revenue growth, %

10%10%15%9%

Cost of goods sold

5.8m6.7m8.5m10.0m

Gross profit

17.4m18.7m20.7m21.8m

Gross profit Margin, %

75%74%71%68%

R&D expense

53.1k41.2k91.8k30.1k

General and administrative expense

14.7m13.5m15.6m14.9m

Operating expense total

16.9m13.7m15.5m16.7m

Depreciation and amortization

154.7k131.6k180.3k206.2k

EBIT

433.6k5.0m5.2m5.1m

EBIT margin, %

2%20%18%16%

Interest expense

947.3k1.3m1.5m1.7m

Pre tax profit

(2.5m)3.6m3.6m3.4m

Income tax expense

(1.2m)1.3m4.5m1.1m

Net Income

(1.3m)2.3m(854.8k)2.3m

Cryo-Cell Balance Sheet

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Cash

3.5m6.3m6.0m6.5m

Accounts Receivable

4.1m5.1m5.9m6.1m

Prepaid Expenses

395.5k372.2k461.8k500.3k

Inventories

361.1k314.6k16.0m1.1m

Current Assets

9.0m12.7m29.5m15.4m

PP&E

979.5k882.4k1.5m1.8m

Goodwill

1.9m1.9m

Total Assets

19.5m23.9m42.4m42.9m

Accounts Payable

1.5m1.9m1.3m1.4m

Short-term debt

2.0m2.0m3.1m3.1m

Current Liabilities

13.1m13.9m15.4m15.4m

Long-term debt

7.8m5.3m9.8m7.3m

Total Debt

9.8m7.3m12.9m10.4m

Total Liabilities

35.0m36.4m51.3m49.8m

Common Stock

125.0k129.0k136.0k136.0k

Additional Paid-in Capital

30.3m31.4m35.5m35.9m

Retained Earnings

(26.8m)(24.5m)(25.3m)(22.4m)

Total Equity

(15.4m)(12.5m)(8.9m)(7.0m)

Debt to Equity Ratio

-0.6 x-0.6 x-1.5 x-1.5 x

Debt to Assets Ratio

0.5 x0.3 x0.3 x0.2 x

Financial Leverage

-1.3 x-1.9 x-4.8 x-6.2 x

Quarterly

USDQ1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2018Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

3.5m4.7m4.7m7.0m6.5m7.0m7.1m6.5m7.3m8.4m8.4m8.1m

Accounts Receivable

4.4m4.6m4.9m4.9m4.8m5.5m5.7m5.8m5.9m5.8m6.0m6.5m

Prepaid Expenses

460.0k498.7k406.1k298.1k488.8k597.0k460.6k61.6k526.3k451.7k684.9k599.4k

Inventories

286.0k296.3k335.8k374.4k424.5k16.2m16.1m1.0m1.0m1.1m1.1m1.2m

Current Assets

9.3m10.7m11.0m13.4m13.0m30.5m30.4m15.0m15.9m16.9m17.3m16.8m

PP&E

933.4k887.6k888.9k1.1m1.0m1.5m1.5m1.7m1.8m1.8m1.7m1.7m

Goodwill

2.0m1.9m1.9m1.9m1.9m1.9m1.9m

Total Assets

19.8m21.0m21.3m21.9m22.2m42.7m43.3m40.9m41.8m44.7m44.8m44.4m

Accounts Payable

1.5m1.2m1.4m1.2m1.1m1.1m1.0m1.0m1.0m1.4m951.9k900.0k

Short-term debt

2.0m2.0m2.0m2.0m2.0m3.1m3.1m3.1m3.1m3.4m3.4m3.4m

Current Liabilities

12.6m13.0m12.6m13.3m12.8m14.9m15.3m13.6m14.3m16.1m15.1m14.4m

Long-term debt

7.4m6.9m5.8m4.8m4.3m11.6m9.1m8.4m8.0m6.8m5.9m4.6m

Total Debt

9.4m8.9m7.8m6.8m6.3m14.7m12.2m11.5m11.1m10.1m9.3m7.9m

Total Liabilities

34.7m35.3m34.7m36.3m36.3m52.5m51.6m49.0m48.8m50.7m49.8m48.5m

Common Stock

128.7k128.9k128.9k129.0k130.7k136.0k136.0k136.0k136.0k136.3k136.3k136.3k

Preferred Stock

Additional Paid-in Capital

30.4m30.9m31.1m31.9m31.6m35.4m35.7m35.7m35.8m36.2m36.2m36.4m

Retained Earnings

(26.3m)(25.8m)(25.2m)(27.0m)(26.5m)(26.2m)(24.5m)(24.4m)(23.3m)(21.8m)(20.8m)(20.0m)

Total Equity

(14.9m)(14.3m)(13.4m)(14.4m)(14.1m)(9.8m)(8.2m)(8.1m)(7.0m)(6.0m)(5.0m)(4.0m)

Debt to Equity Ratio

-0.6 x-0.6 x-0.6 x-0.5 x-0.5 x-1.5 x-1.5 x-1.4 x-1.6 x

Debt to Assets Ratio

0.5 x0.4 x0.4 x0.3 x0.3 x0.3 x0.3 x0.3 x0.3 x

Financial Leverage

-1.3 x-1.5 x-1.6 x-1.5 x-1.6 x-4.3 x-5.3 x-5.1 x-6 x-7.5 x-9 x-11 x

Cryo-Cell Cash Flow

Annual

USDFY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(1.3m)2.3m(854.8k)2.3m

Depreciation and Amortization

286.7k230.0k317.3k401.3k

Accounts Receivable

(1.6m)(1.1m)(1.3m)(997.1k)

Inventories

114.5k46.6k316.7k(27.4k)

Accounts Payable

329.6k443.1k(666.9k)107.5k

Cash From Operating Activities

5.0m5.7m5.3m6.3m

Purchases of PP&E

(343.0k)(98.3k)(446.2k)(662.3k)

Cash From Investing Activities

(369.7k)93.0k(11.3m)(690.7k)

Long-term Borrowings

(1.5m)(2.6m)(3.3m)(4.1m)

Cash From Financing Activities

(5.3m)(3.0m)5.7m(5.1m)

Net Change in Cash

(652.3k)2.8m(239.1k)501.0k

Cryo-Cell Ratios

USDFY, 2016

Revenue/Employee

345.2k

Debt/Equity

-0.6 x

Debt/Assets

0.5 x

Financial Leverage

-1.3 x

Cryo-Cell Operating Metrics

FY, 2016FY, 2017FY, 2018FY, 2019

Cord Blood and Cord Tissue Specimen Stored

300 k450 k500 k500 k

Manufacturing Facilities, sq. ft.

18 k18 k18 k18 k

Cryo-Cell Employee Rating

3.917 votes
Culture & Values
3.6
Work/Life Balance
4.3
Senior Management
3.4
Salary & Benefits
3.6
Career Opportunities
3.3
Source